<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037088</url>
  </required_header>
  <id_info>
    <org_study_id>200614658</org_study_id>
    <secondary_id>C06-DA-119</secondary_id>
    <nct_id>NCT01037088</nct_id>
  </id_info>
  <brief_title>Effects of Vaporized Marijuana on Neuropathic Pain</brief_title>
  <official_title>CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Medicinal Cannabis Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Northern California Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study theorized that a low dose of vaporized cannabis could alleviate nerve injury pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic
      efficacy of vaporized cannabis in subjects, the majority of whom were experiencing
      neuropathic pain despite traditional treatment. Thirty-nine patients with central and
      peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose
      (3.53%), low-dose (1.29%), or placebo cannabis with the primary outcome being visual analog
      scale pain intensity. Psychoactive side effects and neuropsychological performance were also
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With 30% or Greater Reduction in Pain Intensity</measure>
    <time_frame>baseline to six hours</time_frame>
    <description>The primary outcome variable, VAS Pain Intensity, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).An assessment was performed before the administration of vaporized cannabis or placebo and hourly thereafter for six hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale Pain Intensity Scores for Baseline and up to 5 Hours Following Administration of Vaporized Cannabis</measure>
    <time_frame>baseline to six hours</time_frame>
    <description>The pain intensity scores for all of the time points (i.e., baseline prior to administration and up to 5 hours following administration of cannabis). VAS Pain Intensity was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Reflex Sympathetic Dystrophy</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Post-herpetic Neuralgia</condition>
  <condition>Spinal Cord Injury</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mild dose cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.53% THC by weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.29% THC by weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cannabis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo marijuana</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mild dose cannabis</intervention_name>
    <description>3.53% THC by weight</description>
    <arm_group_label>Mild dose cannabis</arm_group_label>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose cannabis</intervention_name>
    <description>1.29% THC by weight</description>
    <arm_group_label>Low dose cannabis</arm_group_label>
    <other_name>marijuana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>0.00% THC by weight</description>
    <arm_group_label>Placebo cannabis</arm_group_label>
    <other_name>placebo marijuana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 and less than 70

          -  Visual Analogue Scale (VAS pain intensity) greater than 3/10

          -  A negative urine drug screening test, i.e., no evidence of IV drug abuse

          -  Neuropathic pain due to reflex sympathetic dystrophy, peripheral neuropathy,
             post-herpetic neuralgia, post-stroke pain, multiple sclerosis or spinal cord injury

        Exclusion Criteria:

          -  Presence of another painful condition of greater severity than the neuropathic pain
             condition which is being studied.

          -  Subjects with moderate-severe major depression, bipolar/mania, bipolar II/hypomania
             and schizophrenia or schizoaffective disorder.

          -  Unstable Type 1 or 2 diabetes defined as blood glucose more than 156 mg/dl

          -  History of traumatic brain injury

          -  Uncontrolled medical condition, including coronary artery disease, hypertension,
             cerebrovascular disease, asthma, tuberculosis (TB), chronic obstructive pulmonary
             disease (COPD), opportunistic infection, malignancy requiring active treatment, active
             substance abuse (alcohol or injection drugs).

          -  Current use of marijuana (e.g., within 30 days of randomization)

          -  Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barth L Wilsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTSC Clinical Research Center, Sacramento VA Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cmcr.ucsd.edu/</url>
    <description>Center for Medicinal Cannabis Research website</description>
  </link>
  <reference>
    <citation>Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008 Jun;9(6):506-21. doi: 10.1016/j.jpain.2007.12.010. Epub 2008 Apr 10.</citation>
    <PMID>18403272</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>April 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>marijuana</keyword>
  <keyword>neuropathy</keyword>
  <keyword>antinociception</keyword>
  <keyword>mood</keyword>
  <keyword>cognition</keyword>
  <keyword>neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place at the UCDMC and VA Northern California Pain clinics,UCDMC Spinal Cord Injury Clinic, and newspaper advertisements. Between December 2009 and March 2011, 59 patients were consented to enroll in the study.</recruitment_details>
      <pre_assignment_details>Twenty subjects did not receive study medication: 9 withdrew for various reasons and 11 were disqualified following a medical evaluation with subsequent disclosure of exclusionary criteria on a physical exam or laboratory finding.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants were randomized to a 3 way cross over design and received 3.53% THC, 1.29% THC and placebo cannabis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 3.53% THC</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1.29% THC</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who were randomized</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With 30% or Greater Reduction in Pain Intensity</title>
        <description>The primary outcome variable, VAS Pain Intensity, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).An assessment was performed before the administration of vaporized cannabis or placebo and hourly thereafter for six hours.</description>
        <time_frame>baseline to six hours</time_frame>
        <population>This was a cross over study. Ten of the 38 subjects who were exposed to placebo had a 30% reduction in pain intensity as compared to 21 of the 37 exposed to the low dose and 22 of the 36 receiving the medium dose of cannabis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Dose Cannabis</title>
            <description>3.53% THC by weight</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cannabis</title>
            <description>1.29% THC by weight</description>
          </group>
          <group group_id="O3">
            <title>Placebo Cannabis</title>
            <description>trace THC by weight</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 30% or Greater Reduction in Pain Intensity</title>
          <description>The primary outcome variable, VAS Pain Intensity, was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).An assessment was performed before the administration of vaporized cannabis or placebo and hourly thereafter for six hours.</description>
          <population>This was a cross over study. Ten of the 38 subjects who were exposed to placebo had a 30% reduction in pain intensity as compared to 21 of the 37 exposed to the low dose and 22 of the 36 receiving the medium dose of cannabis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="45" upper_limit="75"/>
                    <measurement group_id="O2" value="57" lower_limit="41" upper_limit="71"/>
                    <measurement group_id="O3" value="26" lower_limit="15" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale Pain Intensity Scores for Baseline and up to 5 Hours Following Administration of Vaporized Cannabis</title>
        <description>The pain intensity scores for all of the time points (i.e., baseline prior to administration and up to 5 hours following administration of cannabis). VAS Pain Intensity was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).</description>
        <time_frame>baseline to six hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Dose Cannabis</title>
            <description>3.53% THC by weight</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cannabis</title>
            <description>1.29% THC by weight</description>
          </group>
          <group group_id="O3">
            <title>Placebo Cannabis</title>
            <description>0.00% THC by weight</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale Pain Intensity Scores for Baseline and up to 5 Hours Following Administration of Vaporized Cannabis</title>
          <description>The pain intensity scores for all of the time points (i.e., baseline prior to administration and up to 5 hours following administration of cannabis). VAS Pain Intensity was assessed by asking participants to indicate the intensity of their current pain on a 100-mm visual analog scale (VAS) between 0 (no pain) and 100 (worst possible pain).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline prior to Administration of Cannabis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="24.1"/>
                    <measurement group_id="O2" value="54.4" spread="23.4"/>
                    <measurement group_id="O3" value="57.5" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1 after Administration of Cannabis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" spread="22.1"/>
                    <measurement group_id="O2" value="49.8" spread="25.7"/>
                    <measurement group_id="O3" value="56.5" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2 after Administration of Cannabis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="26.8"/>
                    <measurement group_id="O2" value="45.8" spread="26.4"/>
                    <measurement group_id="O3" value="55.4" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3 after Administration of Cannabis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="25.8"/>
                    <measurement group_id="O2" value="38.2" spread="27.1"/>
                    <measurement group_id="O3" value="50.7" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4 after Administration of Cannabis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="26.9"/>
                    <measurement group_id="O2" value="39.5" spread="27.2"/>
                    <measurement group_id="O3" value="48.1" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5 after Administration of Cannabis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="25.5"/>
                    <measurement group_id="O2" value="40.7" spread="27.2"/>
                    <measurement group_id="O3" value="51.8" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hour 1 after Administration of Cannabis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <p_value_desc>not significant</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hour 2 after Administration of Cannabis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=.0002</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hour 3 after Administration of Cannabis (after the second inhalation of cannabis)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hour 4 after Administration of Cannabis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=.0004</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hour 5 after Administration of Cannabis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=.0018</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mild Dose Cannabis</title>
          <description>3.53% 9-delta tetrahydrocannabinol by weight</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Cannabis</title>
          <description>1.29% 9-delta tetrahydrocannabinol by weight</description>
        </group>
        <group group_id="E3">
          <title>Placebo Cannabis</title>
          <description>0% 9-delta tetrahydrocannabinol by weight</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Inclusion of patients with complex regional pain syndrome type I. In the past, there was no doubt that this disorder should be classified as classical neuropathic pain condition; Unmasking of blinding secondary to the psychoactive effects of cannabis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Barth Wilsey, MD</name_or_title>
      <organization>UCaliforniaDavis</organization>
      <phone>916-843-9082</phone>
      <email>blwilsey@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

